Sanofi, AstraZeneca mark big leap toward filing of RSV drug in 2022, with safety data in hand to challenge Synagis
The last big piece of the data package that Sanofi and AstraZeneca needed to file their RSV antibody with the FDA is now in. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
